Sanofi-Aventis announced a new consumer healthcare joint venture with Minsheng Pharmaceutical that will produce vitamins and mineral supplements. Minsheng already manufactures China’s best selling product in the sector: 21-Super Vita multivitamin-multimineral tablets. Although financial details were not disclosed, Sanofi-Aventis did say it would own a majority stake in the JV. More details...

Stock Symbol: (NYSE: SNY)